---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-24-000025"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:19.980412+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco Q2 revenue $1.184B, adjusted EPS $0.30; raises full-year revenue guidance

## Summary
- Q2 revenue $1.184B (+12% reported, +13% CC); pet health $579M (+12%), farm animal $594M (+13%).
- Adjusted EPS $0.30 (+67% YoY); adjusted EBITDA $275M (23.2% margin) vs $222M (21.0%).
- Full year organic CC revenue growth guidance raised to 3%-4% (from 2%-3%); adjusted EPS maintained at $0.88-$0.96.
- Aqua divestiture closed July 9, ~$1.2B proceeds used to pay down debt; gross debt reduced to ~$4.5B; net leverage 5.6x.
- Zenrelia FDA final 60-day review; approval expected late Sept. Bovaer commercial activities underway.

## SEC filing metadata
- accession: 0001739104-24-000025
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000025/0001739104-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000025/elan-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-24-000025
- JSON: https://secwatch.observer/filing/0001739104-24-000025.json
- Plain text: https://secwatch.observer/filing/0001739104-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.